Amedeo Smart

Free Medical Literature Service

 

Amedeo

Head and Neck Cancer
  Free Subscription

Articles published in
Clin Cancer Res
    December 2024
  1. HANNA GJ, Oakley LB, Shi R, ONeill A, et al
    Duvelisib with docetaxel for patients with anti-PD-1 refractory, recurrent or metastatic head and neck squamous cell carcinoma.
    Clin Cancer Res. 2024 Dec 3. doi: 10.1158/1078-0432.CCR-24-2262.
    >> Share

    November 2024
  2. JOHNSON FM, O'Hara MP, Yapindi L, Jiang P, et al
    Phase 1/2 Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas.
    Clin Cancer Res. 2024 Nov 26. doi: 10.1158/1078-0432.CCR-24-2290.
    >> Share

  3. MASTROLONARDO EV, Nunes KL, Llerena P, Nikitina A, et al
    Response-Adaptive Surgical Timing in neoadjuvant immunotherapy demonstrates enhanced pathologic treatment response in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2024 Nov 25. doi: 10.1158/1078-0432.CCR-24-0037.
    >> Share

  4. WANG X, Kang X, Zhang R, Xue L, et al
    Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial.
    Clin Cancer Res. 2024;30:5061-5072.
    >> Share

  5. LI Q, Zhang W, Liao T, Gao Y, et al
    An AI-driven preoperative radiomic subtype for predicting the prognosis and treatment response of patients with papillary thyroid carcinoma.
    Clin Cancer Res. 2024 Nov 13. doi: 10.1158/1078-0432.CCR-24-2356.
    >> Share

    October 2024
  6. HANSEN AR, Gomez-Roca CA, Robbrecht DGJ, Verlingue L, et al
    Phase 1b Study of the Immunocytokine Simlukafusp alfa (FAP-IL2v), in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2024 Oct 18. doi: 10.1158/1078-0432.CCR-24-1562.
    >> Share

  7. CHAMSEDDINE I, Shah K, Lee H, Ehret F, et al
    Decoding Patient Heterogeneity Influencing Radiation-Induced Brain Necrosis.
    Clin Cancer Res. 2024;30:4424-4433.
    >> Share

    September 2024
  8. BARRETT AM, Britton ZT, Carrasco RA, Breen S, et al
    Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancer.
    Clin Cancer Res. 2024 Sep 25. doi: 10.1158/1078-0432.CCR-24-1853.
    >> Share

  9. STONE LD, Kasten BB, Rao S, Gonzalez ML, et al
    Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer.
    Clin Cancer Res. 2024;30:4016-4028.
    >> Share

  10. WARNER BE, Patel J, Wang R, Adams-Haduch J, et al
    The Epstein-Barr virus nuclear antigen 1 variant associated with nasopharyngeal carcinoma defines the sequence criteria for serologic risk prediction.
    Clin Cancer Res. 2024 Sep 12. doi: 10.1158/1078-0432.CCR-24-1142.
    >> Share

    August 2024
  11. SABA NF, Chaudhary R, Kirtane K, Marra A, et al
    Pembrolizumab and cabozantinib in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC): long-term survival update with a biomarker analysis.
    Clin Cancer Res. 2024 Aug 21. doi: 10.1158/1078-0432.CCR-24-1202.
    >> Share

  12. HONMA Y, Monden N, Yamazaki K, Kano S, et al
    Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU.
    Clin Cancer Res. 2024;30:3416-3427.
    >> Share

    July 2024
  13. FORSTER M, Brana I, Lopez Pousa A, Doger B, et al
    Eftilagimod alpha (soluble LAG-3 protein) combined with pembrolizumab as second-line therapy for patients with metastatic head and neck squamous cell carcinoma.
    Clin Cancer Res. 2024 Jul 12. doi: 10.1158/1078-0432.CCR-24-0473.
    >> Share

    June 2024
  14. FRENCH JD, Haugen BR, Worden FP, Bowles DW, et al
    Combination Targeted Therapy with Lenvatinib and Pembrolizumab in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers.
    Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-23-3417.
    >> Share

  15. HANNA GJ, Dennis MJ, Scarfo N, Mullin MS, et al
    Personalized circulating tumor DNA for monitoring disease status in head and neck squamous cell carcinoma.
    Clin Cancer Res. 2024 Jun 2. doi: 10.1158/1078-0432.CCR-24-0590.
    >> Share

    May 2024
  16. SCHMIDT I, Zhao X, van der Waaij AM, Meersma GJ, et al
    Ultrasound-guided quantitative fluorescence molecular endoscopy for monitoring response in patients with esophageal cancer following neoadjuvant chemoradiotherapy.
    Clin Cancer Res. 2024 May 30. doi: 10.1158/1078-0432.CCR-24-0446.
    >> Share

  17. BALLOUT F, Lu H, Bhat N, Chen L, et al
    Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair.
    Clin Cancer Res. 2024;30:2193-2205.
    >> Share

  18. HANNA GJ, Grover P, Elliott A, McGrath J, et al
    Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II.
    Clin Cancer Res. 2024;30:2225-2232.
    >> Share

  19. PENG X, Zhao H, Ye L, Hou F, et al
    Biomarker identification and risk prediction model development for differentiated thyroid carcinoma lung metastasis based on primary lesion proteomics.
    Clin Cancer Res. 2024 May 9. doi: 10.1158/1078-0432.CCR-23-3806.
    >> Share

  20. TANG T, Zhou Z, Chen M, Li N, et al
    Plasma Metabolic Profiles-Based Prediction of Induction Chemotherapy Efficacy in Nasopharyngeal Carcinoma: Results of a Bidirectional Clinical Trial.
    Clin Cancer Res. 2024 May 7. doi: 10.1158/1078-0432.CCR-23-3608.
    >> Share

  21. PRENEN H, Deva S, Keam B, Lindsay CR, et al
    Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer.
    Clin Cancer Res. 2024 May 6. doi: 10.1158/1078-0432.CCR-23-2677.
    >> Share

  22. ROSS RB, Gadwa J, Yu J, Darragh LB, et al
    PPARalpha Agonism Enhances Immune Response to Radiotherapy While Dietary Oleic Acid Results in Counteraction.
    Clin Cancer Res. 2024;30:1916-1933.
    >> Share

  23. LIU Y, Yan W, Hu C, Huang X, et al
    Optimizing Cervical Target Volume in Patients with Nasopharyngeal Cancer Based On Nodal Drainage Distance.
    Clin Cancer Res. 2024;30:1801-1810.
    >> Share

    April 2024
  24. SHANNON NB, Iyer NG
    Unveiling Liquid Gold: Lymph as an HPV Marker in OPSCC to Guide Treatment Decisions.
    Clin Cancer Res. 2024;30:1223-1225.
    >> Share

  25. EARLAND N, Semenkovich NP, Ramirez RJ, Gerndt SP, et al
    Sensitive MRD Detection from Lymphatic Fluid after Surgery in HPV-Associated Oropharyngeal Cancer.
    Clin Cancer Res. 2024;30:1409-1421.
    >> Share

  26. READ ML, Brookes K, Zha L, Manivannan S, et al
    Combined Vorinostat and Chloroquine Inhibit Sodium-Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo.
    Clin Cancer Res. 2024;30:1352-1366.
    >> Share

    March 2024
  27. ZANONI DK, Demetrio De Souza Franca P, Valero C, Peterson G, et al
    A Prospective Double-Blinded Comparison of Reflectance Confocal Microscopy with Conventional Histopathology for In Vivo Assessment in Oral Cancer.
    Clin Cancer Res. 2024 Mar 25. doi: 10.1158/1078-0432.CCR-23-1361.
    >> Share

  28. SWIECICKI PL, Bellile E, Dragovic AF, McHugh J, et al
    Upfront neck dissection for treatment selection and improvement in quality of life as a novel treatment paradigm for deintensification in HPV+ OPSCC.
    Clin Cancer Res. 2024 Mar 22. doi: 10.1158/1078-0432.CCR-23-3247.
    >> Share

  29. KIM CG, Hong MH, Kim D, Lee BH, et al
    A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma.
    Clin Cancer Res. 2024 Mar 8. doi: 10.1158/1078-0432.CCR-23-3249.
    >> Share

  30. JAKOBSEN K, Carlander AF, Todsen T, Melchiors J, et al
    Mesenchymal Stem/Stromal Cell Therapy for Radiation-Induced Xerostomia in Previous Head and Neck Cancer Patients: A Phase 2 Randomised, Placebo-Controlled Trial.
    Clin Cancer Res. 2024 Mar 5. doi: 10.1158/1078-0432.CCR-23-3675.
    >> Share

    February 2024
  31. SAITO S, Kono M, Nguyen HCB, Egloff AM, et al
    Targeting Dendritic Cell Dysfunction to Circumvent anti-PD1 Resistance in Head and Neck Cancer.
    Clin Cancer Res. 2024 Feb 19. doi: 10.1158/1078-0432.CCR-23-3477.
    >> Share

    January 2024
  32. MEHANNA H, Rapozo D, von Zeidler SV, Harrington KJ, et al
    Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study.
    Clin Cancer Res. 2024;30:356-367.
    >> Share

  33. LECHNER MG, Brent GA
    A New Twist on a Classic: Enhancing Radioiodine Uptake in Advanced Thyroid Cancer.
    Clin Cancer Res. 2024 Jan 10. doi: 10.1158/1078-0432.CCR-23-3503.
    >> Share

  34. VON WITZLEBEN A, Ellis M, Thomas GJ, Hoffmann TK, et al
    Tumor-Infiltrating CD103+ Tissue-Resident Memory T Cells and CD103-CD8+ T Cells in HNSCC Are Linked to Outcome in Primary but not Metastatic Disease.
    Clin Cancer Res. 2024;30:224-234.
    >> Share

  35. PENA-OYARZUN D, Flores T, Torres VA, Quest AFG, et al
    Inhibition of PORCN Blocks Wnt Signaling to Attenuate Progression of Oral Carcinogenesis.
    Clin Cancer Res. 2024;30:209-223.
    >> Share

    December 2023
  36. KIM YH, Yoon SJ, Kim M, Kim HH, et al
    Integrative multi-omics analysis reveals different metabolic phenotypes based on molecular characteristics in thyroid cancer.
    Clin Cancer Res. 2023 Dec 13. doi: 10.1158/1078-0432.CCR-23-2025.
    >> Share

    November 2023
  37. NGAMPHAIBOON N, Pattaranutaporn P, Lukerak S, Siripoon T, et al
    A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in Combination with Cetuximab and Radiotherapy (IMRT) for Locally Advanced Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2023 Nov 20. doi: 10.1158/1078-0432.CCR-23-2303.
    >> Share

  38. OU X, Zhai R, Wei W, Chen J, et al
    Induction Toripalimab And Chemotherapy For Organ Preservation In Locally Advanced Laryngeal And Hypopharyngeal Cancer: A Single-Arm Phase 2 Clinical Trial.
    Clin Cancer Res. 2023 Nov 13. doi: 10.1158/1078-0432.CCR-23-2398.
    >> Share

  39. SHEN C, Shi X, Wen D, Zhang Y, et al
    Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System.
    Clin Cancer Res. 2023 Nov 6. doi: 10.1158/1078-0432.CCR-23-2142.
    >> Share

    October 2023
  40. HANNA GJ, Roof SA, Jabalee J, Rettig EM, et al
    Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance.
    Clin Cancer Res. 2023;29:4306-4313.
    >> Share

  41. PIFER PM, Yang L, Kumar M, Xie T, et al
    FAK drives resistance to therapy in HPV-negative head and neck cancer in a p53-dependent manner.
    Clin Cancer Res. 2023 Oct 11. doi: 10.1158/1078-0432.CCR-23-0964.
    >> Share

  42. FU H, Huang J, Zhao T, Wang H, et al
    Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study.
    Clin Cancer Res. 2023 Oct 6. doi: 10.1158/1078-0432.CCR-23-1983.
    >> Share

  43. KLEMPNER SJ, Lee KW, Shitara K, Metges JP, et al
    ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
    Clin Cancer Res. 2023;29:3882-3891.
    >> Share

  44. JAKOBSEN KK, Bendtsen SK, Pallisgaard N, Friborg J, et al
    Liquid Biopsies with Circulating Plasma HPV-DNA Measurements-A Clinically Applicable Surveillance Tool for Patients with HPV-Positive Oropharyngeal Cancer.
    Clin Cancer Res. 2023;29:3914-3923.
    >> Share

    September 2023
  45. DERRY JMJ, Burns C, Frazier JP, Beirne E, et al
    Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment.
    Clin Cancer Res. 2023;29:3813-3825.
    >> Share

  46. DUKE ES, Bradford D, Marcovitz M, Amatya AK, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
    Clin Cancer Res. 2023;29:3573-3578.
    >> Share

  47. LEE MS, Kaseb AO, Pant S
    The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal Cancers.
    Clin Cancer Res. 2023;29:3267-3274.
    >> Share

    August 2023
  48. CHI Y, Zheng X, Zhang Y, Shi F, et al
    Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase â…¡ Trial.
    Clin Cancer Res. 2023 Aug 18:CCR-22-3406. doi: 10.1158/1078-0432.CCR-22-3406.
    >> Share

  49. HEFT NEAL ME, Brenner JC
    Prognosis to Radiation Unlocked: How Hypoxia Methylome May Hold the Key in HNSCC.
    Clin Cancer Res. 2023;29:2954-2956.
    >> Share

  50. TAWK B, Rein K, Schwager C, Knoll M, et al
    DNA-Methylome-Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy.
    Clin Cancer Res. 2023;29:3051-3064.
    >> Share

  51. NIU Z, Sun P, Liu H, Wei P, et al
    Functional Genetic Variants in TGFbeta1 and TGFbetaR1 in miRNA-Binding Sites Predict Outcomes in Patients with HPV-positive Oropharyngeal Squamous Cell Carcinoma.
    Clin Cancer Res. 2023;29:3081-3091.
    >> Share

  52. JACOBS MT, Wong P, Zhou AY, Becker-Hapak M, et al
    Memory-like differentiation, tumor targeting monoclonal antibodies, and chimeric antigen receptors enhance natural killer cell responses to head and neck cancer.
    Clin Cancer Res. 2023 Aug 9:CCR-23-0156. doi: 10.1158/1078-0432.CCR-23-0156.
    >> Share

  53. BEYAERT SP, Loriot AE, Huyghe ND, Goebbels RM, et al
    Tumor microenvironment modifications induced by afatinib in squamous cell carcinoma of the head and neck - a window-of-opportunity study (EORTC90111-24111).
    Clin Cancer Res. 2023 Aug 2:CCR-23-0645. doi: 10.1158/1078-0432.CCR-23-0645.
    >> Share

    July 2023
  54. MORI K, Notsu A, Miura K, Onozawa Y, et al
    MEDI0457 Plus Durvalumab in HPV-associated HNSCC-Letter.
    Clin Cancer Res. 2023;29:2735.
    >> Share

  55. AGGARWAL C, Gong M, Kumar R
    MEDI0457 Plus Durvalumab in HPV-associated HNSCC-Response.
    Clin Cancer Res. 2023;29:2736.
    >> Share

  56. MARON SB, Chatila W, Walch H, Chou JF, et al
    Determinants of survival in HER2+ metastatic esophagogastric cancer.
    Clin Cancer Res. 2023 Jul 5:CCR-22-3769. doi: 10.1158/1078-0432.CCR-22-3769.
    >> Share

  57. HONDERMARCK H, Jiang CC
    Time to Introduce Nerve Density in Cancer Histopathologic Assessment.
    Clin Cancer Res. 2023;29:2342-2344.
    >> Share

    June 2023
  58. SHER DJ, Moon DH, Vo D, Wang J, et al
    Efficacy and quality-of-life following involved nodal radiotherapy for head and neck squamous cell carcinoma: the INRT-AIR phase II clinical trial.
    Clin Cancer Res. 2023 Jun 26:CCR-23-0334. doi: 10.1158/1078-0432.CCR-23-0334.
    >> Share

  59. HU H, Ng TSC, Kang M, Scott E, et al
    Thyroid cancers exhibit oncogene-enhanced macropinocytosis that is restrained by IGF1R and promotes albumin-drug-conjugate response.
    Clin Cancer Res. 2023 Jun 8:CCR-22-2976. doi: 10.1158/1078-0432.CCR-22-2976.
    >> Share

  60. BIKAS A, Ahmadi S, Pappa T, Marqusee E, et al
    Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes.
    Clin Cancer Res. 2023 Jun 1:OF1-OF8. doi: 10.1158/1078-0432.CCR-23-0278.
    >> Share

    May 2023
  61. LIN Y, Qin S, Yang H, Shi F, et al
    Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer.
    Clin Cancer Res. 2023 May 15:CCR-22-3613. doi: 10.1158/1078-0432.CCR-22-3613.
    >> Share

    April 2023
  62. LEBOULLEUX S, Do Cao C, Zerdoud S, Attard M, et al
    A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer.
    Clin Cancer Res. 2023 Apr 19:CCR-23-0046. doi: 10.1158/1078-0432.CCR-23-0046.
    >> Share

  63. PEREZ-PACHECO C, Schmitd LB, Furgal A, Bellile EL, et al
    Increased Nerve Density Adversely Affects Outcome in Oral Cancer.
    Clin Cancer Res. 2023 Apr 11:OF1-OF12. doi: 10.1158/1078-0432.CCR-22-3496.
    >> Share

    February 2023
  64. GULATI S, Crist M, Riaz MK, Takiar V, et al
    Durvalumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, non-randomized, phase-2 clinical trial.
    Clin Cancer Res. 2023 Feb 21:CCR-22-3886. doi: 10.1158/1078-0432.CCR-22-3886.
    >> Share

  65. WILDSMITH S, Li W, Wu S, Stewart R, et al
    Tumor Mutational Burden as a Predictor of Survival With Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2023 Feb 20:CCR-22-2765. doi: 10.1158/1078-0432.CCR-22-2765.
    >> Share

  66. BOUCAI L, Saqcena M, Kuo F, Grewal RK, et al
    Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy.
    Clin Cancer Res. 2023 Feb 13:CCR-22-2882. doi: 10.1158/1078-0432.CCR-22-2882.
    >> Share

  67. WILS LJ, Poell JB, Brink A, Evren I, et al
    Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation.
    Clin Cancer Res. 2023;29:602-613.
    >> Share

  68. GE H, Ferris RL, Wang JH
    Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes.
    Clin Cancer Res. 2023;29:647-658.
    >> Share

    January 2023
  69. OSMAN AA, Arslan E, Bartels M, Michikawa C, et al
    Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2023 Jan 23:CCR-22-2747. doi: 10.1158/1078-0432.CCR-22-2747.
    >> Share

  70. MASCARELLA MA, Olonisakin TF, Rumde P, Vendra V, et al
    Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit.
    Clin Cancer Res. 2023 Jan 3:CCR-22-1768. doi: 10.1158/1078-0432.CCR-22-1768.
    >> Share

    December 2022
  71. HORIBA MN, Casak SJ, Mishra-Kalyani PS, Roy P, et al
    FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease.
    Clin Cancer Res. 2022;28:5244-5248.
    >> Share

  72. MEZGHANI N, Yao A, Vasilyeva D, Kaplan N, et al
    Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry.
    Clin Cancer Res. 2022 Dec 12:CCR-22-2258. doi: 10.1158/1078-0432.CCR-22-2258.
    >> Share

  73. AGGARWAL C, Saba NF, Algazi A, Sukari A, et al
    Safety and Efficacy of MEDI0457 Plus Durvalumab in Patients With Human Papillomavirus-associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2022 Dec 1:CCR-22-1987. doi: 10.1158/1078-0432.CCR-22-1987.
    >> Share

  74. NATHAN CO, Hayes DN, Karrison T, Harismendy O, et al
    A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.
    Clin Cancer Res. 2022;28:5040-5048.
    >> Share

  75. SHI W, Fijardo M, Bruce JP, Su J, et al
    CD8+ Tumor-Infiltrating Lymphocyte Abundance Is a Positive Prognostic Indicator in Nasopharyngeal Cancer.
    Clin Cancer Res. 2022;28:5202-5210.
    >> Share

    November 2022
  76. RODRIGUEZ-RAMIREZ C, Zhang Z, Warner KA, Herzog AE, et al
    p53 Inhibits Bmi-1-driven Self-Renewal and Defines Salivary Gland Cancer Stemness.
    Clin Cancer Res. 2022;28:4757-4770.
    >> Share

  77. FERGUSON AL, Sharman AR, Allen RO, Ye T, et al
    High-Dimensional and Spatial Analysis Reveals Immune Landscape-Dependent Progression in Cutaneous Squamous Cell Carcinoma.
    Clin Cancer Res. 2022;28:4677-4688.
    >> Share

    October 2022
  78. CABANILLAS ME, Busaidy NL, Sherman SI
    Redifferentiation Therapy-Returning to Our Roots in a Post-Kinase Inhibitor World.
    Clin Cancer Res. 2022;28:4164-4166.
    >> Share

  79. COLEVAS AD
    HPV DNA as a Biomarker in Oropharyngeal Cancer: A Step in the Right Direction.
    Clin Cancer Res. 2022;28:4171-4172.
    >> Share

  80. BERGER BM, Hanna GJ, Posner MR, Genden EM, et al
    Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma.
    Clin Cancer Res. 2022;28:4292-4301.
    >> Share

    September 2022
  81. PAUDEL S, Warner BE, Wang R, Adams-Haduch J, et al
    Serological profiling using an Epstein-Barr virus mammalian expression library identifies EBNA1 IgA as a pre-diagnostic marker for nasopharyngeal carcinoma.
    Clin Cancer Res. 2022 Sep 27. pii: 709488. doi: 10.1158/1078-0432.CCR-22-1600.
    >> Share

  82. MIERZWA ML, Aryal M, Lee C, Schipper M, et al
    Randomized Phase II study of Physiologic MRI-directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer.
    Clin Cancer Res. 2022 Sep 15. pii: 709219. doi: 10.1158/1078-0432.CCR-22-1522.
    >> Share

  83. YU M, Moinova HR, Willbanks A, Cannon VK, et al
    Novel DNA Methylation Biomarker Panel for Detection of Esophageal Adenocarcinoma and High-Grade Dysplasia.
    Clin Cancer Res. 2022;28:3761-3769.
    >> Share

  84. ROHRER BLEY C, Wolf F, Goncalves Jorge P, Grilj V, et al
    Dose- and Volume-Limiting Late Toxicity of FLASH Radiotherapy in Cats with Squamous Cell Carcinoma of the Nasal Planum and in Mini Pigs.
    Clin Cancer Res. 2022;28:3814-3823.
    >> Share

    August 2022
  85. QURESHY Z, Li H, Zeng Y, Rivera J, et al
    STAT3 activation as a predictive biomarker for ruxolitinib response in head and neck cancer.
    Clin Cancer Res. 2022 Aug 5. pii: 707467. doi: 10.1158/1078-0432.CCR-22-0744.
    >> Share

  86. LEE YJ, van den Berg NS, Duan H, Azevedo EC, et al
    89Zr-panitumumab combined with 18F-FDG-PET improves detection and staging of head and neck squamous cell carcinoma.
    Clin Cancer Res. 2022 Aug 5. pii: 707464. doi: 10.1158/1078-0432.CCR-22-0094.
    >> Share

  87. YOON HH, Dong H, Shi Q
    Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise.
    Clin Cancer Res. 2022;28:3173-3175.
    >> Share

  88. HONG X, Li Q, Li J, Chen K, et al
    CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization.
    Clin Cancer Res. 2022 Aug 2. pii: 707414. doi: 10.1158/1078-0432.CCR-22-0991.
    >> Share

    July 2022
  89. ZHU M, Chen C, Foster NR, Hartley C, et al
    Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction.
    Clin Cancer Res. 2022;28:3021-3031.
    >> Share

  90. JUNG HA, Park KU, Cho S, Lim J, et al
    A Phase II Study of Nivolumab Plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).
    Clin Cancer Res. 2022 Jul 12. pii: 706988. doi: 10.1158/1078-0432.CCR-22-1238.
    >> Share

  91. SCHMITD LB, Perez-Pacheco C, Bellile EL, Wu W, et al
    Spatial and Transcriptomic Analysis of Perineural Invasion in Oral Cancer.
    Clin Cancer Res. 2022 Jul 12:OF1-OF16. doi: 10.1158/1078-0432.CCR-21-4543.
    >> Share

  92. LYNGGAARD CD, Gronhoj C, Jensen SB, Christensen R, et al
    Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial.
    Clin Cancer Res. 2022;28:2890-2897.
    >> Share

    June 2022
  93. ZHANG Z, Wu B, Peng G, Xiao G, et al
    Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial.
    Clin Cancer Res. 2022 Jun 29:OF1-OF9. doi: 10.1158/1078-0432.CCR-22-0666.
    >> Share

  94. SIHAG S, Nussenzweig SC, Walch HS, Hsu M, et al
    The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma.
    Clin Cancer Res. 2022;28:2669-2678.
    >> Share

  95. DUKE ES, Barone AK, Chatterjee S, Mishra-Kalyani PS, et al
    FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.
    Clin Cancer Res. 2022 Jun 9. pii: 704846. doi: 10.1158/1078-0432.CCR-22-0873.
    >> Share

  96. LEE KW, Van Cutsem E, Bang YJ, Fuchs CS, et al
    Association of Tumor Mutational Burden with Efficacy of Pembrolizumab{plus minus}Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.
    Clin Cancer Res. 2022 Jun 3. pii: 699374. doi: 10.1158/1078-0432.CCR-22-0121.
    >> Share

  97. LEDDON JL, Gulati S, Haque S, Allen C, et al
    Phase 2 trial of adjuvant nivolumab following salvage resection in patients with recurrent squamous cell carcinoma of the head and neck.
    Clin Cancer Res. 2022 Jun 2. pii: 699312. doi: 10.1158/1078-0432.CCR-21-4554.
    >> Share

    May 2022
  98. WANG W, Lozar T, Golfinos AE, Lee D, et al
    Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockade.
    Clin Cancer Res. 2022 May 27:OF1-OF16. doi: 10.1158/1078-0432.CCR-21-3039.
    >> Share

  99. SCHMITD LB, Perez-Pacheco C, Bellile EL, Wu W, et al
    Spatial and Transcriptomic Analysis of Perineural Invasion in Oral Cancer.
    Clin Cancer Res. 2022 May 26. pii: 699248. doi: 10.1158/1078-0432.CCR-21-4543.
    >> Share

  100. WEBER M, Kersting D, Riemann B, Brandenburg T, et al
    Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancer With MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study.
    Clin Cancer Res. 2022 May 20. pii: 699089. doi: 10.1158/1078-0432.CCR-22-0437.
    >> Share

  101. DENEKA AY, Baca Y, Serebriiskii IG, Nicolas E, et al
    Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer.
    Clin Cancer Res. 2022;28:1925-1937.
    >> Share

    April 2022
  102. LE X, Gleber-Netto FO, Rubin ML, Qing Y, et al
    Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection.
    Clin Cancer Res. 2022 Apr 20. pii: 694632. doi: 10.1158/1078-0432.CCR-21-3239.
    >> Share

  103. FERRAROTTO R, Amit M, Nagarajan P, Rubin ML, et al
    Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
    Clin Cancer Res. 2022;28:1735.
    >> Share

  104. LEE AW, Ng WT, Choi CW, But B, et al
    Exploratory Study of NPC-0501 Trial - Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2022 Apr 5. pii: 694221. doi: 10.1158/1078-0432.CCR-21-3375.
    >> Share

  105. GUIX I, Liu Q, Pujana MA, Ha P, et al
    Validation of Anticorrelated TGFbeta Signaling and Alternative End-Joining DNA Repair Signatures that Predict Response to Genotoxic Cancer Therapy.
    Clin Cancer Res. 2022;28:1372-1382.
    >> Share

    March 2022
  106. CHUNG CH, Li J, Steuer CE, Bhateja P, et al
    Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma.
    Clin Cancer Res. 2022 Mar 28. pii: 694028. doi: 10.1158/1078-0432.CCR-21-3849.
    >> Share

  107. OKADA M, Kato K, Cho BC, Takahashi M, et al
    Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3).
    Clin Cancer Res. 2022 Mar 16. pii: 682194. doi: 10.1158/1078-0432.CCR-21-0985.
    >> Share

  108. RICKELT S, Neyaz A, Condon C, Whittaker CA, et al
    Agrin Loss in Barrett's Esophagus-Related Neoplasia and Its Utility as a Diagnostic and Predictive Biomarker.
    Clin Cancer Res. 2022;28:1167-1179.
    >> Share

  109. OBRADOVIC A, Graves D, Korrer M, Wang Y, et al
    Immunostimulatory cancer-associated fibroblast subpopulations can predict immunotherapy response in head and neck cancer.
    Clin Cancer Res. 2022 Mar 9. pii: 682113. doi: 10.1158/1078-0432.CCR-21-3570.
    >> Share

    February 2022
  110. WISE-DRAPER TM, Gulati S, Palackdharry S, Hinrichs BH, et al
    Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2022 Feb 28:OF1-OF8. doi: 10.1158/1078-0432.CCR-21-3351.
    >> Share

  111. XU Y, Dong B, Zhu W, Li J, et al
    A phase III multicenter randomized clinical trial of 60 Gy vs 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma.
    Clin Cancer Res. 2022 Feb 18. pii: 681705. doi: 10.1158/1078-0432.CCR-21-3843.
    >> Share

  112. SACCO AG, Cohen EEW
    Inevitable Progress-Relying on the Immune System, Not Chance.
    Clin Cancer Res. 2022;28:435-437.
    >> Share

    January 2022
  113. FERRIS RL, Moskovitz J, Kunning S, Ruffin AT, et al
    Phase I trial of cetuximab, radiation therapy, and ipilimumab in locally advanced head and neck cancer.
    Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-0426.
    >> Share

  114. KAO HF, Liao BC, Huang YL, Huang HC, et al
    Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis.
    Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-3025.
    >> Share

  115. LI Y, Yang X, Du X, Lei Y, et al
    Correction: RAB37 Hypermethylation Regulates Metastasis and Resistance to Docetaxel-Based Induction Chemotherapy in Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2022;28:430.
    >> Share

  116. CAO Y, Haring CT, Brummel C, Bhambhani C, et al
    Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma.
    Clin Cancer Res. 2022;28:350-359.
    >> Share

    December 2021
  117. WEBER P, Kunstner A, Hess J, Unger K, et al
    Therapy-related transcriptional subtypes in matched primary and recurrent head and neck cancer.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-2244.
    >> Share

  118. COHEN EEW, Nabell L, Wong DJ, Day T, et al
    Intralesional SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive head and neck squamous cell carcinoma: results from a multicenter, phase 2 trial.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-1411.
    >> Share

  119. LUGINBUHL AJ, Johnson JM, Harshyne LA, Linnenbach AJ, et al
    Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma.
    Clin Cancer Res. 2021 Dec 15. pii: 1078-0432.CCR-21-1816.
    >> Share

  120. YAP TA, Vieito M, Baldini C, Sepulveda-Sanchez JM, et al
    First-In-Human Phase I Study of a Next-Generation, Oral, TGFbeta Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer.
    Clin Cancer Res. 2021;27:6666-6676.
    >> Share

  121. PANG J, Nguyen N, Luebeck J, Ball L, et al
    Extrachromosomal DNA in HPV-Mediated Oropharyngeal Cancer Drives Diverse Oncogene Transcription.
    Clin Cancer Res. 2021;27:6772-6786.
    >> Share

  122. TAYLOR MH, Betts CB, Maloney L, Nadler E, et al
    Safety and Efficacy of Pembrolizumab in Combination With Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
    Clin Cancer Res. 2021 Dec 3. pii: 1078-0432.CCR-21-2547.
    >> Share

  123. SIRAVEGNA G, O'Boyle CJ, Varmeh S, Queenan N, et al
    Cell free HPV DNA provides an accurate and rapid diagnosis of HPV-associated head and neck cancer.
    Clin Cancer Res. 2021 Dec 2. pii: 1078-0432.CCR-21-3151.
    >> Share

  124. EVEN C, Wang HM, Li SH, Ngan RK, et al
    Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer.
    Clin Cancer Res. 2021;27:6413-6423.
    >> Share

    November 2021
  125. KATABATHULA R, Joseph P, Singh S, Zhao S, et al
    Multi-scale Pan-cancer Integrative Analyses Identify the STAT3-VSIR Axis as a key Immunosuppressive Mechanism in Head and Neck Cancer.
    Clin Cancer Res. 2021 Nov 16. pii: 1078-0432.CCR-21-1978.
    >> Share

  126. BICKETT TE, Knitz M, Darragh LB, Bhatia S, et al
    FLT3L Release by Natural Killer Cells Enhances Response to Radioimmunotherapy in Preclinical Models of HNSCC.
    Clin Cancer Res. 2021;27:6235-6249.
    >> Share

  127. LEUNG E, Han K, Zou J, Zhao Z, et al
    HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA.
    Clin Cancer Res. 2021;27:5857-5868.
    >> Share

    October 2021
  128. HANNA GJ, ONeill A, Shin KY, Wong K, et al
    Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.
    Clin Cancer Res. 2021 Oct 19. pii: 1078-0432.CCR-21-2635.
    >> Share

    September 2021
  129. ZHANG JX, Chen ZH, Xu Y, Chen JW, et al
    Correction: Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell-like Phenotype via Dysregulation of PITX2.
    Clin Cancer Res. 2021;27:4942.
    >> Share

  130. DE LA IGLESIA JV, Slebos RJC, Martin-Gomez L, Wang X, et al
    Correction: Effects of Tobacco Smoking On the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2021;27:4941.
    >> Share

    August 2021
  131. VYAS A, Harbison RA, Faden DL, Kubik M, et al
    Recurrent human papillomavirus-related head and neck cancer undergoes metabolic re-programming and is driven by oxidative phosphorylation.
    Clin Cancer Res. 2021 Aug 18. pii: 1078-0432.CCR-20-4789.
    >> Share

  132. XIA WX, Lv X, Liang H, Liu GY, et al
    A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer.
    Clin Cancer Res. 2021;27:4186-4194.
    >> Share

    July 2021
  133. ZHENG X, Xu Z, Ji Q, Ge M, et al
    A randomized, phase 3 study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer.
    Clin Cancer Res. 2021 Jul 29. pii: 1078-0432.CCR-21-0761.
    >> Share

  134. BRAND TM, Hartmann S, Bhola NE, Peyser ND, et al
    Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV(+) Patients.
    Clin Cancer Res. 2021;27:4129.
    >> Share

  135. KARPINETS TV, Mitani Y, Liu B, Zhang J, et al
    Whole-Genome Sequencing of Common Salivary Gland Carcinomas: Subtype-Restricted and Shared Genetic Alterations.
    Clin Cancer Res. 2021;27:3960-3969.
    >> Share

  136. CHENG NM, Yao J, Cai J, Ye X, et al
    Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging.
    Clin Cancer Res. 2021;27:3948-3959.
    >> Share

  137. LABIANO S, Roh V, Godfroid C, Hiou-Feige A, et al
    CD40 Agonist Targeted to Fibroblast Activation Protein alpha Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors.
    Clin Cancer Res. 2021;27:4054-4065.
    >> Share

  138. DE CLERCQ NC, van den Ende T, Prodan A, Hemke R, et al
    Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study.
    Clin Cancer Res. 2021;27:3784-3792.
    >> Share

    June 2021
  139. FERRAROTTO R, Amit M, Nagarajan P, Rubin ML, et al
    Pilot phase II trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
    Clin Cancer Res. 2021 Jun 29. pii: 1078-0432.CCR-21-0585.
    >> Share

  140. BURGENER JM, Zou J, Zhao Z, Zheng Y, et al
    Tumor-Naive Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2021 Jun 22. pii: 1078-0432.CCR-21-0110.
    >> Share

  141. VAN DEN ENDE T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, et al
    Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT).
    Clin Cancer Res. 2021;27:3351-3359.
    >> Share

  142. PAPPA T, Ahmadi S, Marqusee E, Johnson HL, et al
    Oncogenic mutations in PI3K/AKT/mTOR pathway effectors associate with worse prognosis in BRAF(V600E)-driven papillary thyroid cancer patients.
    Clin Cancer Res. 2021 Jun 4. pii: 1078-0432.CCR-21-0874.
    >> Share

  143. OPENSHAW MR, Pinato DJ, Valeri N
    Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer.
    Clin Cancer Res. 2021;27:2964-2966.
    >> Share

  144. HEGDE A, Jayaprakash P, Couillault CA, Piha-Paul S, et al
    A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
    Clin Cancer Res. 2021;27:3050-3060.
    >> Share

  145. PENG Z, Wei J, Wang F, Ying J, et al
    Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
    Clin Cancer Res. 2021;27:3069-3078.
    >> Share

  146. CORSO S, Pietrantonio F, Apicella M, Migliore C, et al
    Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas.
    Clin Cancer Res. 2021;27:3126-3140.
    >> Share

    May 2021
  147. LEE RH, Kang H, Yom SS, Smogorzewska A, et al
    Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes.
    Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-1259.
    >> Share

  148. KIM J, Bradford D, Larkins E, Pai-Scherf LH, et al
    FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid cancers with RET gene mutations or fusions.
    Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-0967.
    >> Share

    April 2021
  149. LI D, Chi Y, Chen X, Ge MH, et al
    Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
    Clin Cancer Res. 2021 Apr 8. pii: 1078-0432.CCR-20-2950.
    >> Share

  150. CATENACCI DVT
    A PERFECT biomarker-focused study of neoadjuvant IO for esophagogastric cancer.
    Clin Cancer Res. 2021 Apr 6. pii: 1078-0432.CCR-21-0324.
    >> Share

  151. WAINBERG ZA, Fuchs CS, Tabernero J, Shitara K, et al
    Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score >/=10.
    Clin Cancer Res. 2021;27:1923-1931.
    >> Share

    March 2021
  152. LEI M, Siemers NO, Pandya D, Chang H, et al
    Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab{plus minus}Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
    Clin Cancer Res. 2021 Mar 29. pii: 1078-0432.CCR-20-2790.
    >> Share

  153. ZHAO M, Scott S, Evans KW, Yuca E, et al
    Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.
    Clin Cancer Res. 2021;27:1681-1694.
    >> Share

    February 2021
  154. KLEIN S, Quaas A, Quantius J, Loser H, et al
    Deep Learning Predicts HPV Association in Oropharyngeal Squamous Cell Carcinomas and Identifies Patients with a Favorable Prognosis Using Regular H&E Stains.
    Clin Cancer Res. 2021;27:1131-1138.
    >> Share

  155. FERRAROTTO R, Mitani Y, McGrail DJ, Li K, et al
    Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets.
    Clin Cancer Res. 2021;27:852-864.
    >> Share

    January 2021
  156. WATERMANN C, Pasternack H, Idel C, Ribbat-Idel J, et al
    Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion.
    Clin Cancer Res. 2021;27:632-644.
    >> Share

    December 2020
  157. THAKUR S, Daley B, Millo C, Cochran C, et al
    (177)Lu-DOTA-EB-TATE, A Radiolabeled Analog of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer.
    Clin Cancer Res. 2020 Dec 22. pii: 1078-0432.CCR-20-3453.
    >> Share

    November 2020
  158. BRADFORD D, Larkins E, Mushti SL, Rodriguez L, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions.
    Clin Cancer Res. 2020 Nov 25. pii: 1078-0432.CCR-20-3558.
    >> Share

    September 2020
  159. GRAY KD, McCloskey JE, Vedvyas Y, Kalloo OR, et al
    PD1 blockade enhances ICAM1-directed CAR T therapeutic efficacy in advanced thyroid cancer.
    Clin Cancer Res. 2020 Sep 4. pii: 1078-0432.CCR-20-1523.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016